Comparison
3 Methylglutaconic Aciduria Type 2 C0574083 vs 3 M Syndrome C1848862
Clinical comparison between 3 Methylglutaconic Aciduria Type 2 and 3 M Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 2 C0574083
Also called Barth syndrome, this genetic condition primarily affects males and impairs mitochondrial function. It causes heart muscle weakness, muscle weakness, and recurrent infections. Treatment includes cardiac care, infection prevention, and supportive therapies.
3 M Syndrome C1848862
A rare genetic syndrome causing severe short stature and distinctive facial features. Affects bone development. Treatment involves growth monitoring and orthopedic care.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 2 C0574083
0-5
3 M Syndrome C1848862
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 2 C0574083
severe
3 M Syndrome C1848862
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 2 C0574083
Chronic
3 M Syndrome C1848862
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 2 C0574083
No
3 M Syndrome C1848862
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3 M Syndrome C1848862
musculoskeletal
Same/different system
Category
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3 M Syndrome C1848862
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-2-C0574083 and 3-m-syndrome-C1848862 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3 M Syndrome C1848862 | Discriminating power |
|---|---|---|---|
| Growth pattern | Growth may be impaired, but extreme short stature is not the defining feature. | Severe prenatal or postnatal short stature is characteristic. | High |
| Heart involvement | Cardiomyopathy or heart-muscle weakness is typical. | Primary cardiomyopathy is not an established feature. | High |
| Infection tendency | Neutropenia may be associated with recurrent infections. | Recurrent infection is not a core feature. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 2 C0574083 when
Male infant with cardiomyopathy and muscle weakness
This pattern fits Barth syndrome better than a primary skeletal growth disorder.
High
Neutropenia with suspected organic aciduria
Metabolic abnormalities support Barth syndrome only when correlated clinically.
Moderate
Family history suggesting X-linked inheritance
Barth syndrome typically affects males through X-linked inheritance.
Moderate
Choose 3 M Syndrome C1848862 when
Severe short stature with distinctive facial features
Growth and skeletal findings are central to 3-M syndrome.
High
Skeletal changes without cardiomyopathy
A musculoskeletal phenotype without heart disease favors 3-M syndrome.
Moderate
Variants in CUL7, OBSL1, or CCDC8
These genes are associated with 3-M syndrome rather than Barth syndrome.
High
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3 M Syndrome C1848862 | Interpretation |
|---|---|---|---|
| Urine organic acids | 3-methylglutaconic acid may be elevated; this is not diagnostic alone. | No specific organic aciduria is expected. | An abnormal result supports Barth syndrome only with clinical and genetic correlation. |
| Echocardiography | May show cardiomyopathy or reduced heart function. | Primary cardiomyopathy is not expected. | Cardiac abnormality, when present, strongly favors Barth syndrome. |
| Genetic testing | TAFAZZIN (TAZ) variant, typically X-linked. | Biallelic CUL7, OBSL1, or CCDC8 variant. | Molecular results can distinguish them; clinician confirmation is required. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 2 C0574083
- Outcome
- Often serious and variable because of possible heart disease, neutropenia, and muscle weakness.
- Factors
- Cardiac function, infections, nutrition, growth, and access to specialist care.
3 M Syndrome C1848862
- Outcome
- Usually compatible with life; short stature and musculoskeletal effects are the main concerns. Cognitive impairment is not defining.
- Factors
- Degree of growth restriction, skeletal complications, and associated findings.
Time frame: Both are lifelong; major needs often emerge in infancy or childhood.
Confirmed genetics, complication severity, and multidisciplinary support influence outcomes.
Complications comparison
| Complication | Presentation |
|---|---|
| Heart failure | Cardiomyopathy may lead to heart failure or arrhythmia. Heart failure is not a typical complication. Cardiac surveillance is central in Barth syndrome. |
| Serious infection | Neutropenia may increase infection risk. Serious infection is not characteristic. Fever in suspected Barth syndrome needs prompt assessment. |
| Skeletal complications | Muscle weakness may occur, but skeletal dysplasia is not defining. Short stature and bone-development concerns may require orthopedic care. 3-M syndrome centers on growth and musculoskeletal effects. |
Patient education highlights
- HighSpecialist follow-up
Both conditions are chronic and genetic, but monitoring and treatment priorities differ and should be individualized.
- HighWarning symptoms
For Barth syndrome, seek urgent care for breathing difficulty, fainting, poor feeding, or fever. For 3-M syndrome, report pain or growth concerns.
- MediumGenetic counseling
Inheritance patterns differ. Counseling can help families understand testing and recurrence risk.